We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sham Citizen Petitions by Branded Drugmakers to FDA in Senate’s Crosshairs
Sham Citizen Petitions by Branded Drugmakers to FDA in Senate’s Crosshairs
July 30, 2021
Brand-name drug companies could soon face civil penalties for filing sham citizen petitions with the FDA that seek to stop approval of generic or biosimilar competitors under a bill that has advanced to the full Senate.